The NIH-funded Regenerative Medicine Innovation Catalyst will: ? Provide in-depth and independent characterization of the source stem cell line and stem cell-derived products being developed, ? Provide a platform for sharing and analysis of clinical trial (if applicable) and cell product characterization data, thereby potentially enabling correlation of stem cell-derived product attributes with clinical outcomes, and ? Create a foundation for enhancing our understanding of clinical outcomes, refining production methods, and informing future RM product development. Importantly, the RMIC will promote transparency and ultimately may contribute to reproducibility and standardization of clinical grade stem cell-derived products.
|Effective start/end date||10/1/19 → 9/30/20|
- National Heart, Lung, and Blood Institute: $100,000.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.